Fresenius SE & Co KGaA (FRE) Given a €59.00 Price Target by UBS Group Analysts

Fresenius SE & Co KGaA (FRA:FRE) has been given a €59.00 ($70.24) price objective by equities research analysts at UBS Group in a report released on Friday, January 5th, www.boersen-zeitung.de reports. The firm presently has a “sell” rating on the stock. UBS Group’s price target suggests a potential downside of 9.81% from the company’s current price.

A number of other brokerages have also recently issued reports on FRE. S&P Global set a €85.00 ($101.19) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Monday, November 6th. Commerzbank set a €85.00 ($101.19) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Monday, November 6th. Bank of America set a €75.00 ($89.29) target price on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Monday, November 6th. Goldman Sachs Group set a €78.00 ($92.86) price target on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Monday, November 6th. Finally, Deutsche Bank set a €84.00 ($100.00) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of €78.66 ($93.65).

Shares of Fresenius SE & Co KGaA (FRA FRE) opened at €65.42 ($77.88) on Friday. Fresenius SE & Co KGaA has a 52 week low of €60.16 ($71.62) and a 52 week high of €80.00 ($95.24). The firm has a market capitalization of $36,290.00 and a PE ratio of 20.83.

ILLEGAL ACTIVITY NOTICE: “Fresenius SE & Co KGaA (FRE) Given a €59.00 Price Target by UBS Group Analysts” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/fresenius-se-59-00-price-target-by-ubs-group-analysts.html.

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply